No Data
Hengdian Group Capital and Apeloa Pharmaceutical to Participate in 2025 J.P. Morgan Healthcare Conference
Apeloa Pharmaceutical Gets Approval to Conduct Clinical Trials for Semaglutide Injection; Shares Up 3%
Investors Don't See Light At End Of Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Tunnel
Apeloa Pharmaceutical (000739.SZ): The clinical trial application for Kangyu Pharmaceutical's semaglutide injection for weight management and adult type 2 diabetes indications has been approved.
Gelonghui, January 2nd丨Apeloa Pharmaceutical (000739.SZ) announced that recently, its holding subsidiary Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd. (referred to as "Kangyu Pharmaceutical") received the "Notice of Approval for Clinical Trials" issued by the National Medical Products Administration (Notice Number: 2024LP02958, 2024LP02959, 2024LP02960, 2024LP02961, 2024LP02962, 2024LP02963, 2024LP02964). Kangyu Pharmaceutical applied for the import of semaglutide.
Apeloa PharmaceuticalLtd (SZSE:000739) Investors Are Sitting on a Loss of 50% If They Invested Three Years Ago
Apeloa Pharmaceutical Gets Drug Registration for Influenza Treatment
Is Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
